Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Hydromethylthionine
2. Hydromethylthionine Mesylate
3. Leuco-methylthioninium
4. Leucomethylene Blue
5. Leukomethylene Blue
6. Lmtx Compound
7. Panatone
8. Trx0237
1. 1236208-20-0
2. Leucomethylene Blue Mesylate
3. Leucomethylene Blue (mesylate)
4. Hydromethylthionine Mesylate
5. N3,n3,n7,n7-tetramethyl-10h-phenothiazine-3,7-diamine Dimethanesulfonate
6. Leucomethylene Blue Bismesylate
7. Lmtm
8. Trx-0237 Dimesylate
9. 3248sef29d
10. Hydromethylthionine Mesylate [usan]
11. Methanesulfonic Acid;3-n,3-n,7-n,7-n-tetramethyl-10h-phenothiazine-3,7-diamine
12. Trx0237
13. Leuco-methylthioninium Dimesylate
14. Trx-0237
15. Lmtx
16. 10h-phenothiazine-3,7-diamine, N3,n3,n7,n7-tetramethyl-, Methanesulfonate (1:2)
17. Trx-0237 Mesylate
18. Trx0237 Dimesylate
19. Trx0237 (lmtx)
20. Unii-3248sef29d
21. Chembl4297221
22. Bcp16840
23. Ex-a1927
24. Mfcd29764308
25. Akos026750731
26. Cs-5553
27. Leucomethylene Blue Mesylate; Trx0237
28. Hy-19948
29. Ms-28864
30. Leucomethylene Blue; Bis(methanesulfonic Acid)
31. A922039
32. Trx0237 Mesylate;methylene Blue Leuco Base Mesylate
33. Leuco-methylthioninium Bis(hydromethanesulfonate)
34. 3,7-bis(dimethylamino)phenothiazin-5-ium Methanesulfonate
35. N3,n3,n7,n7-tetramethyl-10h-phenothiazine-3,7-diaminedimethanesulfonate
36. N,n,n',n'-tetramethyl-10h-phenothiazine-3,7-diaminium Bis(methanesulfonate)
1. Hydromethylthionine Mesylate
| Molecular Weight | 477.6 g/mol |
|---|---|
| Molecular Formula | C18H27N3O6S3 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 10 |
| Rotatable Bond Count | 2 |
| Exact Mass | g/mol |
| Monoisotopic Mass | g/mol |
| Topological Polar Surface Area | 169 |
| Heavy Atom Count | 30 |
| Formal Charge | 0 |
| Complexity | 396 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 3 |
Drugs in Development
Details:
TRx0237 (hydromethylthionine mesylate), is an investigational small molecule Tau protein inhibitor, for the treatment of mild to moderate Alzheimer’s disease. The company has submitted MAA in UK.
Lead Product(s): Hydromethylthionine Mesylate
Therapeutic Area: Neurology Brand Name: TRx0237
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 01, 2024
Lead Product(s) : Hydromethylthionine Mesylate
Therapeutic Area : Neurology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
TauRx Submits UK Marketing Application for HMTM as Alzheimer’s Disease Treatment
Details : TRx0237 (hydromethylthionine mesylate), is an investigational small molecule Tau protein inhibitor, for the treatment of mild to moderate Alzheimer’s disease. The company has submitted MAA in UK.
Product Name : TRx0237
Product Type : Small molecule
Upfront Cash : Not Applicable
July 01, 2024
Details:
TauRx's lead product candidate TRx0237 (hydromethylthionine), a tau protein inhibitor. Currently, it is being evaluated in the Phase 3 clinical trial studies for the treatment of Alzheimer's disease.
Lead Product(s): Hydromethylthionine Mesylate
Therapeutic Area: Neurology Brand Name: TRx0237
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 07, 2024
Lead Product(s) : Hydromethylthionine Mesylate
Therapeutic Area : Neurology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
TauRx's LUCIDITY Trial Indicates Two-Year Sustained Cognitive Benefits of HMTM
Details : TauRx's lead product candidate TRx0237 (hydromethylthionine), a tau protein inhibitor. Currently, it is being evaluated in the Phase 3 clinical trial studies for the treatment of Alzheimer's disease.
Product Name : TRx0237
Product Type : Small molecule
Upfront Cash : Not Applicable
March 07, 2024
Details:
TRx0237 is a small molecule drug being tested for its ability to inhibit aggregation of tau, a protein that forms neurofibrillary tangles in the brains of people with Alzheimer's and other neurodegenerative diseases.
Lead Product(s): Hydromethylthionine Mesylate
Therapeutic Area: Neurology Brand Name: TRx0237
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 30, 2022
Lead Product(s) : Hydromethylthionine Mesylate
Therapeutic Area : Neurology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : TRx0237 is a small molecule drug being tested for its ability to inhibit aggregation of tau, a protein that forms neurofibrillary tangles in the brains of people with Alzheimer's and other neurodegenerative diseases.
Product Name : TRx0237
Product Type : Small molecule
Upfront Cash : Not Applicable
November 30, 2022
Details:
HMTM or TRx0237 is an oral tau aggregation inhibitor, targeting this underlying pathology. TauRx’s HMTM has the potential to become the first disease-modifying therapies (DMT) targeting tau to be approved for AD.
Lead Product(s): Hydromethylthionine Mesylate
Therapeutic Area: Neurology Brand Name: TRx0237
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Undisclosed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing November 14, 2022
Lead Product(s) : Hydromethylthionine Mesylate
Therapeutic Area : Neurology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Undisclosed
Deal Type : Financing
Details : HMTM or TRx0237 is an oral tau aggregation inhibitor, targeting this underlying pathology. TauRx’s HMTM has the potential to become the first disease-modifying therapies (DMT) targeting tau to be approved for AD.
Product Name : TRx0237
Product Type : Small molecule
Upfront Cash : Undisclosed
November 14, 2022
Details:
For people with early Alzheimer’s (MCI), HMTM, a potent inhibitor of Tau aggregation treatment resulted in sustained improvement in cognition over pre-treatment baseline, and normalisation of brain atrophy to a rate similar to healthy individuals.
Lead Product(s): Hydromethylthionine Mesylate
Therapeutic Area: Neurology Brand Name: TRx0237
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 06, 2022
Lead Product(s) : Hydromethylthionine Mesylate
Therapeutic Area : Neurology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
TauRx Announces Results from Phase 3 Alzheimer’s Disease Study, LUCIDITY, Assuring Path for Regu...
Details : For people with early Alzheimer’s (MCI), HMTM, a potent inhibitor of Tau aggregation treatment resulted in sustained improvement in cognition over pre-treatment baseline, and normalisation of brain atrophy to a rate similar to healthy individuals.
Product Name : TRx0237
Product Type : Small molecule
Upfront Cash : Not Applicable
October 06, 2022
Details:
TauRx's lead investigative oral drug, TRx0237, has been tested in 598 people with Alzheimer's. Following our 12 month blinded phase of the study, participants have moved forward to an additional one year open label phase.
Lead Product(s): Hydromethylthionine Mesylate
Therapeutic Area: Neurology Brand Name: TRx0237
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2022
Lead Product(s) : Hydromethylthionine Mesylate
Therapeutic Area : Neurology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : TauRx's lead investigative oral drug, TRx0237, has been tested in 598 people with Alzheimer's. Following our 12 month blinded phase of the study, participants have moved forward to an additional one year open label phase.
Product Name : TRx0237
Product Type : Small molecule
Upfront Cash : Not Applicable
June 01, 2022
Details:
This milestone means TauRx will now progress to the data cleaning and analysis phase which enables the company to determine topline results on the safety and efficacy of Hydromethylthionine mesylate (HMTM).
Lead Product(s): Hydromethylthionine Mesylate
Therapeutic Area: Neurology Brand Name: TRx0237
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 14, 2022
Lead Product(s) : Hydromethylthionine Mesylate
Therapeutic Area : Neurology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
TauRx's Late-Stage Clinical Trial Reaches New Milestone
Details : This milestone means TauRx will now progress to the data cleaning and analysis phase which enables the company to determine topline results on the safety and efficacy of Hydromethylthionine mesylate (HMTM).
Product Name : TRx0237
Product Type : Small molecule
Upfront Cash : Not Applicable
April 14, 2022
Details:
Minimum dose of hydromethylthionine could slow clinical decline and brain atrophy in behavioural variant Fronto-Temporal Dementia as well as Alzheimer's Disease.
Lead Product(s): Hydromethylthionine Mesylate
Therapeutic Area: Neurology Brand Name: TRx0237
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 19, 2020
Lead Product(s) : Hydromethylthionine Mesylate
Therapeutic Area : Neurology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
TauRx Reveals Study Results That Offer New Hope for Treatment of Patients With Dementia
Details : Minimum dose of hydromethylthionine could slow clinical decline and brain atrophy in behavioural variant Fronto-Temporal Dementia as well as Alzheimer's Disease.
Product Name : TRx0237
Product Type : Small molecule
Upfront Cash : Not Applicable
May 19, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
